Catalyst Brief

← Calendar

Readoutin 104d

Pierre Fabre Medicament — Encorafenib and Binimetinib

Phase 3 primary completion: Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation..

Date
Mar 2027
Type
Readout
Indication
Melanoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.